FDA Approves Merck’s RSV Prevention Treatment for Infants
TL;DR Summary
The FDA has approved Merck's ENFLONSIA, a monoclonal antibody for preventing RSV lower respiratory tract disease in infants during their first RSV season, offering a single, weight-independent dose providing protection for about 5 months based on clinical trial success.
- U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season Merck.com
- FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca CNBC
- Merck Says It Wins US Approval for Shot to Prevent Infant RSV Bloomberg
- US FDA approves Merck's RSV antibody for infants Reuters
- Merck’s RSV antibody treatment for infants is approved by FDA statnews.com
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
8 min
vs 9 min read
Condensed
98%
1,673 → 39 words
Want the full story? Read the original article
Read on Merck.com